GleamWall
中文EN

IPSC Century Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850119 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,556.5%
TTM net income YoY92.4%
TTM EPS YoY91.3%
Revenue 3-yr CAGR175.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15.8%
Net margin-8.8%
FCF margin-95.9%
EBITDA margin-3.8%

Returns

ROE-6.0%
ROA-3.3%
ROIC (approx.)-13.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio5.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income10.85x
Accruals ratio32.7%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$109.16M$4.17M
R&D expense$18.06M$19.59M$17.11M$19.70M$22.53M$26.86M$26.58M$29.38M
SG&A expense$7.15M$5.79M$6.58M$956,000$6.83M$7.80M$8.41M$7.75M
Operating income-$25.21M-$36.53M-$23.68M-$20.65M-$36.12M-$34.66M$74.18M-$37.28M
Pretax income———-$19.24M-$34.42M-$32.54M$76.56M-$34.30M
Income tax———————$1.78M
Net income-$23.45M-$34.55M-$21.64M-$19.17M-$34.42M-$32.54M$76.56M-$36.07M
EBITDA-$23.02M-$36.50M-$20.68M-$17.10M-$32.99M-$31.46M$77.40M-$33.97M
EPS (basic)-0.11-0.17-0.11—-0.40-0.380.89—
EPS (diluted)-0.11-0.17-0.11—-0.40-0.380.89—
Weighted avg. shares (diluted)206.44M205.78M193.47M—86.46M86.24M86.10M—
Balance sheet
Cash & equivalents$45.02M$49.64M$51.05M$61.85M$58.67M$59.59M$54.64M$61.21M
Short-term investments$72.19M$70.07M$83.75M$55.26M$77.23M$98.97M$113.26M$130.85M
Current assets$122.71M$124.77M$139.04M$120.77M$137.71M$160.17M$169.63M$194.05M
PP&E, net$32.83M$34.48M$47.61M$50.03M$53.72M$56.65M$59.53M$62.14M
Intangibles$34.20M$34.20M$34.20M$34.20M$34.20M$34.20M$34.20M$34.20M
Total assets$262.63M$287.01M$326.55M$223.70M$244.72M$284.69M$315.61M$353.22M
Current liabilities$14.04M$15.07M$13.57M$20.23M$22.03M$14.95M$14.50M$129.78M
Total liabilities$52.66M$54.66M$61.81M$64.77M$68.37M$74.79M$75.17M$191.85M
Shareholders' equity$209.97M$232.34M$264.74M$158.94M$176.35M$209.90M$240.44M$161.36M
Shares outstanding181.24M180.55M180.10M87.52M86.53M86.32M86.15M85.84M
Cash flow statement
Operating cash flow-$22.23M-$19.83M-$25.26M-$16.08M-$25.58M-$27.59M-$34.62M-$24.22M
Capital expenditure$535,000$694,000$584,000-$139,000$195,000$317,000$475,000—
Free cash flow-$22.76M-$20.53M-$25.85M-$15.94M-$25.78M-$27.91M-$35.10M—
Investing cash flow$17.53M$17.77M-$112.61M$22.36M$24.67M$32.54M$27.93M$30.61M
Financing cash flow$76,000$311,000$126.62M$53,000$0$0$120,000-$602,000
Depreciation & amortization$2.19M$26,000$3.00M$3.55M$3.13M$3.20M$3.22M$3.32M
Stock-based compensation$1.44M$1.95M$1.45M$1.30M$891,000$2.22M$2.43M$2.66M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.